Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Glycemic variability in chronic calcific pancreatitis with diabetes mellitus and its possible determinants","authors":"Amarta Shankar Chowdhury ,&nbsp;Rajan Palui ,&nbsp;Subhodip Pramanik ,&nbsp;Sunetra Mondal","doi":"10.1016/j.dsx.2024.103100","DOIUrl":"10.1016/j.dsx.2024.103100","url":null,"abstract":"<div><h3>Aims</h3><p>To study glycemic patterns and variability in patients with pancreatic diabetes or type 3c Diabetes mellitus (DM) due to chronic pancreatitis and its subtypes and assess the role of pancreatic enzyme replacement therapy (ERT) in modulating glycemic variability.</p></div><div><h3>Methods</h3><p>Patients having type 3c DM due to chronic pancreatitis, and on insulin underwent Flash continuous-glucose-monitoring (CGM) for 14 days. Parameters were compared between patients with fibrocalculous pancreatic diabetes (FCPD) and non-FCPD-chronic calcific pancreatitis (non-FCPD) and between the recipients and non-recipients of pancreatic enzyme-replacement-therapy (ERT).</p></div><div><h3>Results</h3><p>Out of 54 patients with pancreatic diabetes, 35 patients had chronic calcific pancreatitis. They underwent CGM, median HbA1c 9.20 % (77 mmol/mol) and mean Time-In-Range (TIR) being 41.21 % (23.48). Only 5 (15.2 %) patients achieved target TIR&gt;70 % while 16 (48.5 %) patients had high glycemic-variability [Coefficient-of-variation (CV) &gt; 36 %]. Patients with FCPD (n = 14) had higher hypoglycemia-indices like Time-Below-Range (18.92 % vs 8.20 %; p = 0.03) and Low-Blood-Glucose-Index (18.14 % vs 6.04 %; p = 0.02) compared to non-FCPD (n = 21). HbA1c% and hyperglycemic excursions were similar in both groups. Recipients of ERT (n = 20) had lower glycemic-variability [Standard Deviation (SD) 52.15 % vs 68.14 % and CV 32.59 % vs 41.79 %, p &lt; 0.05 for both) than non-recipients. ERT-recipients had no serious hypoglycemia within the 14 days. On subgroup analysis, lower glycemic-variability and hypoglycemia with ERT were seen only in FCPD but not in non-FCPD subgroup (50.13 vs 77.91, 30.09 vs 48.36 for SD and CV respectively, p &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>Patients with type 3c DM due to chronic pancreatitis have high frequency of hyperglycemic and hypoglycemic excursions, with those with FCPD having a particularly higher risk of hypoglycemia and glycemic-variability. Those receiving pancreatic ERT had lesser glycemic variability and hypoglycemia. The small sample size and lack of objective markers of documentation of exocrine pancreatic insufficiency like fecal elastase highlight the need for further larger studies in this field.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103100"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of lipid disturbances in psoriasis: An analysis of trends from 2006 to 2023","authors":"Miao Zhang ,&nbsp;Siwei Fan ,&nbsp;Seokgyeong Hong ,&nbsp;Xiaoying Sun ,&nbsp;Yaqiong Zhou ,&nbsp;Liu Liu ,&nbsp;Jiao Wang ,&nbsp;Chunxiao Wang ,&nbsp;Naixuan Lin ,&nbsp;Xiayi Xiao ,&nbsp;Xin Li","doi":"10.1016/j.dsx.2024.103098","DOIUrl":"10.1016/j.dsx.2024.103098","url":null,"abstract":"<div><h3>Introduction</h3><p>A strong link has been established between psoriasis and lipid disturbances; however, no study has systematically examined their global epidemiology.</p></div><div><h3>Methods</h3><p>We searched six databases from their inception up to October 1, 2023. Data analysis was conducted using Stata SE 15.1. We performed subgroup, meta-regression, and sensitivity analyses to assess the heterogeneity of the pooled studies.</p></div><div><h3>Results</h3><p>Our review included 239 studies comprising 15,519,570 participants. The pooled prevalence rate of dyslipidemia among individuals with psoriasis was 38 %.</p></div><div><h3>Conclusion</h3><p>Patients with severe psoriasis should undergo screening for lipid abnormalities. This can facilitate the early detection of lipid dysfunction and associated cardiovascular comorbidities.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103098"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of stigma perception by people with type 1 diabetes: A cross-sectional analysis of the BETTER registry","authors":"Asmaa Housni ,&nbsp;Alexandra Katz ,&nbsp;Jessica C. Kichler ,&nbsp;Meranda Nakhla ,&nbsp;Laurence Secours ,&nbsp;Anne-Sophie Brazeau","doi":"10.1016/j.dsx.2024.103112","DOIUrl":"10.1016/j.dsx.2024.103112","url":null,"abstract":"<div><h3>Aims</h3><p>This study investigates stigma predictors across ages and genders, addressing a critical gap in understanding diverse populations to reduce related suboptimal clinical and psychosocial outcomes.</p></div><div><h3>Methods</h3><p>Cross-sectional analysis of self-reported data from BETTER, a Canadian registry of people with type 1 diabetes. Participants (n = 709) completed the 19-item-Diabetes-Stigma Assessment-Scale (DSAS-1) categorized into <em>treated differently</em>, <em>blame and judgment</em>, and <em>identity concerns</em> sub-scales. Associations with diabetes distress (DDS-17-score/102), depression (PHQ-9-score/27), social-support (ESSI-score/34), fear of hypoglycemia (HFS-II-score/132), and hyperglycemia-avoidance-behaviours (HAS-score/88) were computed.</p></div><div><h3>Results</h3><p>Perceived stigma was highest in youth aged 14–24 years (46·0 ± 15·6, p &lt; 0·001) and women (41·2 ± 15·7, p = 0·009), compared to other age groups and men. <em>Blame and Judgment</em> contributed to most of stigma perception. Youth perceived significantly more blame and judgment (p &lt; 0·001) and identity concerns (p = 0·001) compared to middle-aged adults and seniors. Women perceive significantly more blame and judgment compared to men (p &lt; 0·001). The perception of <em>being treated differently</em> was not reported to be an issue across ages and genders. Participants with higher scores of depression, diabetes-distress, fear of hypoglycemia, hyperglycemia-avoidance behaviours, and lesser social-support, reported increased stigma.</p></div><div><h3>Conclusions</h3><p>Stigma varies by age and gender, underscoring the need for targeted interventions to reduce it. Challenging stereotypes and reducing stigma-related stressors are essential for better outcomes.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103112"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001735/pdfft?md5=322ddc4106656f1e5814dbc5bf9abfd5&pid=1-s2.0-S1871402124001735-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the therapeutic targets of stevioside in management of type 2 diabetes by network pharmacology and in-silico approach","authors":"Amit Dutta ,&nbsp;Md. Arju Hossain ,&nbsp;Pratul Dipta Somadder ,&nbsp;Mahmuda Akter Moli ,&nbsp;Kawsar Ahmed ,&nbsp;Md Masuder Rahman ,&nbsp;Francis M. Bui","doi":"10.1016/j.dsx.2024.103111","DOIUrl":"10.1016/j.dsx.2024.103111","url":null,"abstract":"<div><h3>Aims</h3><p>The main objective of the current study is to investigate the pathways and therapeutic targets linked to stevioside in the management of T2D using computational approaches.</p></div><div><h3>Methods</h3><p>We collected RNA-seq datasets from NCBI, then employed GREIN to retrieve differentially expressed genes (DEGs). Computer-assisted techniques DAVID, STRING and NetworkAnalyst were used to explore common significant pathways and therapeutic targets associated with T2D and stevioside. Molecular docking and dynamics simulations were conducted to validate the interaction between stevioside and therapeutic targets.</p></div><div><h3>Results</h3><p>Gene ontology and KEGG analysis revealed that prostaglandin synthesis, IL-17 signaling, inflammatory response, and interleukin signaling were potential pathways targeted by stevioside in T2D. Protein-protein interactions (PPI) analysis identified six common hub proteins (<em>PPARG</em>, <em>PTGS2</em>, <em>CXCL8</em>, <em>CCL2</em>, <em>PTPRC</em>, and <em>EDN1</em>). Molecular docking results showed best binding of stevioside to <em>PPARG</em> (−8 kcal/mol) and <em>PTGS2</em> (−10.1 kcal/mol). Finally, 100 ns molecular dynamics demonstrated that the binding stability between stevioside and target protein (PPARG and PTGS2) falls within the acceptable range.</p></div><div><h3>Conclusions</h3><p>This study reveals that stevioside exhibits significant potential in controlling T2D by targeting key pathways and stably binding to <em>PPARG</em> and <em>PTGS2</em>. Further research is necessary to confirm and expand upon these significant computational results.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103111"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001723/pdfft?md5=489797dde5f3b993f00592182637b904&pid=1-s2.0-S1871402124001723-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices","authors":"Mohammad-Hossein Keivanlou ,&nbsp;Ehsan Amini-Salehi ,&nbsp;Nazila Sattari ,&nbsp;Mohammad Hashemi ,&nbsp;Parsa Saberian ,&nbsp;Shrinidhi Vilas Prabhu ,&nbsp;Mona Javid ,&nbsp;Arian Mirdamadi ,&nbsp;Forough Heidarzad ,&nbsp;Arash Bakhshi ,&nbsp;Negin Letafatkar ,&nbsp;Reza Zare ,&nbsp;Soheil Hassanipour ,&nbsp;Sandeep Samethadka Nayak","doi":"10.1016/j.dsx.2024.103110","DOIUrl":"10.1016/j.dsx.2024.103110","url":null,"abstract":"<div><h3>Background</h3><p>We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.</p></div><div><h3>Method</h3><p>A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.</p></div><div><h3>Result</h3><p>A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P &lt; 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P &lt; 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P &lt; 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P &lt; 0.001, respectively).</p></div><div><h3>Conclusion</h3><p>Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103110"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials","authors":"Ridhima Kaul ,&nbsp;Pradipta Paul ,&nbsp;Manale Harfouche ,&nbsp;Muhammad Ayyan ,&nbsp;Sa'ad Laws ,&nbsp;Ali Chaari","doi":"10.1016/j.dsx.2024.103118","DOIUrl":"10.1016/j.dsx.2024.103118","url":null,"abstract":"<div><h3>Background</h3><p>Metabolic syndrome (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and carbohydrate metabolism. Microbiome-modulating probiotics, prebiotics, synbiotics and fecal microbiota transplant (FMT) are promising adjunct therapies for improving parameters of glucose homeostasis and insulinemia.</p></div><div><h3>Methods</h3><p>We conducted a comprehensive systematic review, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening clinical trials published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions.</p></div><div><h3>Results</h3><p>Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting plasma glucose (MD: 4.03 mg/dL [95%CI: 6.93; −1.13]; p _effect = 0.006, I² = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; −0.84]; p _effect = 0.004, I² = 87.9 %), but not insulin resistance or sensitivity indices and HbA1c. Age, baseline BMI, baseline biomarker value, pro/synbiotic dosage, trial duration, nutraceutical type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged glucose homeostasis in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application.</p></div><div><h3>Conclusions</h3><p>Probiotics, prebiotics, synbiotics and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103118"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001796/pdfft?md5=92841c8feaf77c6c18ca25c46fd5778f&pid=1-s2.0-S1871402124001796-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study","authors":"Fu-Shun Yen ,&nbsp;James Cheng-Chung Wei ,&nbsp;Ying-Hsiu Shih ,&nbsp;Yu-Tung Hung ,&nbsp;Tzu-Ju Hsu ,&nbsp;Chih-Cheng Hsu ,&nbsp;Chii-Min Hwu","doi":"10.1016/j.dsx.2024.103099","DOIUrl":"10.1016/j.dsx.2024.103099","url":null,"abstract":"<div><h3>Aims</h3><p>To compare the risk of vision-threatening retinopathy between glucagon-like peptide-1 receptor agonists (GLP-1 RA) use and no use in patients with type 2 diabetes.</p></div><div><h3>Methods</h3><p>Using propensity score matching, we identified 27,506 pairs of GLP-1 RA users and non-users, 3904 pairs of GLP-1 RA and dipeptidyl peptidase-4 inhibitors (DPP-4i) users, 10,985 pairs of GLP-1 RA and sodium-glucose cotransporter-2 inhibitors (SGLT2i) users, 2542 pairs of GLP-1 RA and sulfonylurea, respectively, from Taiwan's National Health Insurance Research Database from January 1, 2009 to December 31, 2018. We used Cox proportional hazards models to compare the risk of vision-threatening retinopathy between GLP-1 RA use and other matched groups.</p></div><div><h3>Results</h3><p>In the matched cohorts, the time-varying exposure analysis showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to GLP-1 RA non-use (aHR 0.96, 95 % CI 0.89–1.03). New-user and active-comparator analyses showed that GLP-1 RA was associated with a significantly lower risk of vision-threatening retinopathy than DPP-4i (aHR 0.8, 95 % CI 0.66–0.97) but had no significant association with this risk compared to SGLT2i (aHR 1.09, 95 % CI 0.96–1.24) or sulfonylureas (aHR 0.79, 95 % CI 0.49–1.06).</p></div><div><h3>Conclusions</h3><p>This nationwide cohort study showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to non- GLP-1 RA use, and GLP-1 RA could significantly lower the risk of vision-threatening retinopathy than DPP-4i.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103099"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: No increased incidence of retinopathy linked to hydroxychloroquine in RA patients with diabetes","authors":"","doi":"10.1016/j.dsx.2024.103101","DOIUrl":"10.1016/j.dsx.2024.103101","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103101"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the Current Issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103125","DOIUrl":"10.1016/j.dsx.2024.103125","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103125"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142318616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential manifestation of type 2 diabetes in Black Africans and White Europeans with recently diagnosed type 2 diabetes: A systematic review","authors":"Davis Kibirige ,&nbsp;Ronald Olum ,&nbsp;Andrew Peter Kyazze ,&nbsp;Bethan Morgan ,&nbsp;Felix Bongomin ,&nbsp;William Lumu ,&nbsp;Moffat J. Nyirenda","doi":"10.1016/j.dsx.2024.103115","DOIUrl":"10.1016/j.dsx.2024.103115","url":null,"abstract":"<div><h3>Aims</h3><p>The clinical manifestation of type 2 diabetes (T2D) varies across populations. We compared the phenotypic characteristics of Black Africans and White Europeans with recently diagnosed T2D to understand the ethnic differences in the manifestation of T2D.</p></div><div><h3>Methods</h3><p>We searched Medline, EMBASE, CINAHL, Google Scholar, African Index Medicus, and Global Health for studies reporting information on phenotypic characteristics in Black Africans and White Europeans with recently diagnosed T2D.</p></div><div><h3>Results</h3><p>A total of 28 studies were included in this systematic review (14 studies conducted on 2586 Black Africans in eight countries and 14 studies conducted on 279,621 White Europeans in nine countries). Compared with White Europeans, Black Africans had a lower pooled mean (95 % confidence interval) age (51.5 [48.5–54.4] years vs. 60.2 [57.9–62.6] years), body mass index (27.0 [24.2–29.8] kg/m² vs. 31.3 [30.5–32.1] kg/m²), and a higher pooled median glycated haemoglobin (9.0 [8.0–10.3]% vs. 7.1 [6.7–7.7]%). Ugandan and Tanzanian participants had lower markers of beta-cell function and insulin resistance when compared with four White European populations.</p></div><div><h3>Conclusion</h3><p>These findings provide evidence of the ethnic differences in the manifestation of T2D, underscoring the importance of understanding the underlying factors influencing these differences and formulating ethnic-specific approaches for managing and preventing T2D.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103115"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}